Catalent (NYSE:CTLT) Receiving Somewhat Positive Media Coverage, Report Shows
News stories about Catalent (NYSE:CTLT) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catalent earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.5396907271226 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
A number of research analysts have commented on CTLT shares. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “hold” rating in a research note on Friday, March 9th. KeyCorp upgraded shares of Catalent from a “sector weight” rating to an “overweight” rating and set a $48.00 price objective on the stock in a research note on Wednesday, March 28th. ValuEngine lowered shares of Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, June 5th. UBS Group upgraded shares of Catalent from a “market perform” rating to an “outperform” rating in a research note on Wednesday, March 21st. Finally, Raymond James upgraded shares of Catalent from a “market perform” rating to an “outperform” rating and set a $48.00 price target on the stock in a research note on Wednesday, March 21st. They noted that the move was a valuation call. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $45.67.
Shares of Catalent stock traded up $1.28 on Thursday, reaching $41.54. 783,100 shares of the stock were exchanged, compared to its average volume of 830,790. The company has a quick ratio of 1.78, a current ratio of 2.18 and a debt-to-equity ratio of 2.53. Catalent has a 1-year low of $33.42 and a 1-year high of $47.87. The firm has a market cap of $5.29 billion, a price-to-earnings ratio of 30.77, a price-to-earnings-growth ratio of 2.11 and a beta of 1.50.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.